The Medical Letter on Drugs and Therapeutics
In Brief: Transdermal Rotigotine (Neupro)
Download PDF:   US English
Med Lett Drugs Ther. 2012 Aug 20;54(1397):68
 Select a term to see related articles  Mirapex   neupro   Parkinson's disease   Pramipexole   Requip   Restless legs syndrome   Ropinirole   rotigotine 

A patch formulation of the non-ergot dopamine agonist rotigotine (Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early Parkinson’s disease,1 it was withdrawn in 2008 because of crystallization of the drug in the patch, which could have led to under-dosing. The new patch has somewhat broader indications than the old one; it is approved for use in any stage of Parkinson’s disease (PD) and also for moderate-to-severe restless legs syndrome (RLS).

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article